WebJul 13, 2024 · Investor Relations - Innoviva Sells 15% Economic Stake in Theravance Respiratory Company to Royalty Pharma for approximately $282 million plus full ownership of existing equity investments and the potential for $50 million milestone payment - Innoviva Skip to main navigation About Strategic Assets Team Strategy Investor Relations WebPavel Raifeld. Chief Executive Officer. Read Bio. Marianne Zhen, CPA. Chief Accounting Officer. Read Bio. Investor Relations ... Board of Directors; Management; Committee Composition; Stock Information. Overview; SEC Filings; Email Alerts Subscription; Contact Us; Innoviva. Mar 31, 2024 11:12 PM EDT. Data Provided by Refinitiv. Minimum 15 ...
Innoviva Names Pavel Raifeld as Chief Executive Officer
WebFeb 3, 2024 · Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: “RELVAR ® /BREO ® ELLIPTA ® global net sales increased by 5%, ANORO ® ELLIPTA ® global net sales increased by 10%, and ... WebPavel Raifeld, CFA Healthcare executive and investor New York, New York, United States 2K followers 500+ connections Join to view profile Innoviva Activity I'm looking forward … enable screenshot on mac
Innoviva enters agreement to acquire La Jolla Pharmaceutical …
WebJul 11, 2024 · Through the acquisition of Entasis, Innoviva has gained an exciting pipeline, created a new growth channel and diversified its revenue stream,” said Pavel Raifeld, … WebPavel Raifeld, Innoviva Inc: Profile and Biography - Bloomberg Markets Bloomberg Connecting decision makers to a dynamic network of information, people and ideas, … WebSep 21, 2024 · Pavel Raifeld, Chief Executive Officer of Innoviva, said: “In 2024, Trelegy Ellipta was approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD, and it remains the market leader with strong continued growth. ... Innoviva's portfolio is anchored by the respiratory assets partnered with Glaxo Group ... enable scripthook fivem